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EDITORIAL
Cyclic AMP, at the hub of the cystic cycle
Half a century after its discovery, new roles for adeno-
sine 3′,5′-cyclic monophosphate (cAMP) continue to be
discovered. The article by Belibi et al [1] in this issue
of Kidney International, implicates cAMP in the patho-
genesis of autosomal-dominant and recessive polycystic
kidney diseases (ADPKD and ARPKD) and provides a
target for the pharmacologic treatment of these disorders.
Cyclic AMP is a ubiquitous and versatile second
messenger. Extracellular ligands bind to G protein–
coupled receptors (GPCR) that positively (Gs) or neg-
atively (Gi) regulate closely associated adenylyl cyclases
(ACs). Cyclic AMP levels are controlled within specific
cellular compartments by the activity of cAMP phos-
phodiesterases (PDEs), themselves subject to complex
regulatory mechanisms. Maximal rates of degradation
by PDEs exceed those of synthesis by ACs, point-
ing to the importance of PDEs in the regulation of
cAMP signaling. Cyclic AMP may exit the cells by an
energy-dependent transport mechanism, but in most cells
efflux does not have a major effect on cAMP levels.
Biological effects of cAMP are mediated by protein ki-
nase A (PKA), cyclic nucleotide gated cation channels,
and guanine nucleotide exchange factors. PKA is targeted
to specific cellular compartments by A kinase–anchoring
proteins (AKAPs). The specificity of cAMP signaling is
achieved by the extraordinary diversity of ACs, PDEs,
PKAs, and AKAPs. It also depends on cell-type specific
cross-talk with other signaling systems, such as mitogen-
activated protein kinase/extracellular-regulated kinase
(MAPK/ERK) cascades that couple growth factor recep-
tors and Ras to cell proliferation. They consist of three
protein kinases acting in series, a MAP kinase kinase ki-
nase (MAPKKK), which activates a MAP kinase kinase
(MAPKK or MEK), which phosphorylates a MAP kinase
(MAPK or ERK). In the ERK1/2 cascade, the Raf fam-
ily of serine/threonine protein kinases (A-Raf, B-Raf, and
Raf-1) function as MAPKKK. Activated PKA catalytic
subunits and ERKs can translocate to the nucleus where
they phosphorylate transcription factors. Calcium in in-
tracellular compartments ([Ca2+]i) that may be directly
affected by polycystic kidney disease (PKD)-causing ge-
netic alterations can regulate positively and negatively
cAMP and MAPK signaling.
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In the last 15 years, Grantham et al have gathered a
wealth of evidence pointing to a major cAMP role in
cystogenesis by promoting fluid secretion and cell pro-
liferation (reviewed in [2]). Initially, they reported that
cAMP enhances the growth of Madin-Darby canine kid-
ney (MDCK) cell subconfluent monolayers, the transep-
ithelial movement of fluid across polarized MDCK cell
monolayers on permeable supports, and the enlargement
of MDCK and ADPKD microcysts in hydrated collagen
gels. Further studies established that fluid secretion by
ADPKD epithelia, as well as by normal collecting ducts,
is driven by chloride entering the cell via basolateral
Na+/Cl− or Na+/K+/2Cl− cotransporters and exiting via
apical cAMP-dependent Cl− channels. Then they noted,
along with Hanaoka et al [3], that cAMP activates the
ERK cascade and increases the proliferation of ADPKD
cells, while exerting inhibitory effects on normal human
kidney cortex cells. More recently, their research showed
that the treatment of collecting duct (M-1) cells with
calcium channel blockers replicates the abnormal pro-
liferative response of the ADPKD cells to cAMP, thus
linking the cystic phenotype to the reduction in [Ca2+]i
that likely results from disrupting the polycystin pathway.
While the precise underlying mechanism remains to be
elucidated, their preliminary observations suggest an in-
hibition of Ca2+ dependent PI3 kinase activity with down-
stream inhibition of Akt and activation of B-Raf kinase
(Yamaguchi et al, ISN 2003 abstract).
Because cAMP modulates cellular functions in a cell-
specific manner, the cellular composition of the cysts
may be relevant to their pathogenesis and the capacity
of pharmacologic interventions to influence the course
of ADPKD and ARPKD. While there is general agree-
ment that the cysts in ARPKD derive from collecting
ducts, the cysts in ADPKD have been thought to arise
from all segments of the nephron and collecting duct. A
detailed histochemical study of 10 ADPKD kidneys, in
which cysts were defined as tubular dilatations at least
1 mm in diameter, challenged this view [4]. In this study,
70% of the cysts stained positively for collecting duct
markers, while the remaining 30% were negative for all
markers, possibly due to cellular dedifferentiation. Simi-
lar results have been obtained in the Pkd2−/WS25 mouse
model of ADPKD [5, 6]. Other studies using aquaporin
(AQP) antibodies showed that 30% of the cysts, but only
11% of large cysts, were positive for AQP1 (presumably
from proximal tubular origin) [7]. Because these obser-
vations were made mostly in kidneys with advanced or
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end-stage renal disease, it is possible that obstruction
and acquired renal cystic disease could account for the
observed proximal tubular dilatations and small cysts.
Therefore, it seems likely that in both cases, ARPKD and
ADPKD, cysts are predominantly of collecting duct ori-
gin, at least at early stages. The markedly higher cAMP
production in response to vasopressin as compared to
parathyroid hormone, in the article by Belibi et al, is con-
sistent with this interpretation [1].
Recent publications suggest that an increased renal
accumulation of cAMP is a feature common to sev-
eral rodent models of PKD, including the pcy mouse,
the PCK rat, and the Pkd2−/WS25 mouse [6, 8, 9]. This
is surprising because previous studies have shown re-
duced cAMP accumulation in cells cultured from cpk
kidneys [10] and adenylyl cyclase hyporesponsiveness
to agonist stimulation in cultured cells and cysts freshly
isolated from human ADPKD kidneys [11]. In this is-
sue of Kidney International, Belibi et al [1] have rigor-
ously evaluated the responses of human ADPKD and
ARPKD cyst epithelial cells to physiologically important
adenylyl cyclase agonists. The rank order of responses
was identical for both types of cells: epinephrine>
desmopressin> adenosine> prostaglandin E2> parathy-
roid hormone, with effects ranging from 5.7% (ARPKD
cells, PTH) to 95.8% (ADPKD cells, epinephrine) of
maximal forskolin-induced stimulation. While these re-
sults demonstrate that these agonists are capable to
stimulate cAMP production in target cells from hu-
man renal cysts, the relative strengths of stimulation, as
the authors recognize, may not hold in situ. A previ-
ous study has shown that adenylyl cyclase stimulation
by epinephrine acting on b-adrenergic receptors was
markedly enhanced, while the adenylyl cyclase inhibi-
tion by epinephrine acting on a2-adrenergic receptors
was markedly blunted in cultured as compared to freshly
isolated inner medullary collecting ducts [12]. In freshly
isolated collecting ducts the changes in cAMP produc-
tion induced by b-adrenergic and other adenylyl cyclase
agonists are very small compared to those induced by
physiologic concentrations of vasopressin. Furthermore,
agonists in vivo do not work in isolation; agents, that in
isolation stimulate adenylyl cyclase in vitro, may have an
inhibitory effect in vivo by interacting with other more
potent agonists [13]. In addition, the maximally effective
agonist concentrations used by Belibi et al may be differ-
ent from those that are physiologically relevant. Among
the cAMP agonists tested in their study, the novel cyst-
activating factor (CAF), present in the renal cyst fluids,
appears to be particularly potent. Its precise chemical
structure and its role in early and advanced polycystic
kidney disease remain to be elucidated.
The mechanism underlying the increased levels of
cAMP in polycystic kidneys has not been established, but
a number of hypotheses can be considered. The PC1 C-
terminal tail binds heterotrimeric G proteins and may act
as a GPCR, which, when activated by ligand binding or
extracellular matrix proteins, initiates Gi-mediated sig-
naling [14]. By this mechanism PC1 might regulate in-
tracellular cAMP, and a disruption of its function could
result in the elevated levels. A reduction in intracellu-
lar calcium due to disruption of the polycystin pathway
could result in the stimulation of calcium inhibitable AC6
[15] and the inhibition of calcium/calmodulin dependent
PDE1 [16]. AC6 is the main AC isoform, and PDE1, along
with PDE4, is the main PDE isoform in the collecting
duct principal cells. Some PDE4 isozymes are phospho-
rylated and inhibited by ERK2 [17], which is known to
be activated in PKD. Finally, abnormal AQP2 traffic due
to altered [Ca2+]i homeostasis or disrupted medullary
architecture due to cysts could cause the concentration
defect common to all forms of PKD and explain the in-
creased cAMP levels as a maladaptive response attempt-
ing to compensate for this defect. Consistent with this
hypothesis are the increased circulating vasopressin lev-
els in human ADPKD [18] and the renal up-regulation
of vasopressin V2 receptor and AQP2 mRNA in several
animal models of polycystic kidney disease, including the
cpk, pcy, and Pkd2−/WS25 mice, and the PCK rat [6, 9, 19].
Observations that the collecting duct is the predomi-
nant site of cystogenesis in ARPKD and ADPKD, that
vasopressin (via V2 receptors) is the major adenylyl cy-
clase agonist in principal cells, and that cAMP promotes
cystogenesis, have provided a strong rationale for treat-
ing animal models of PKD with vasopressin V2 receptor
(VPV2R) antagonists [6, 9]. The administration of the
VPV2R antagonist OPC31260 has recently been shown
to lower renal cAMP and markedly inhibit disease de-
velopment in models of ARPKD (PCK rat), ADPKD
(Pkd2WS25/− mouse), and adolescent nephronophthisis
(pcy mouse). Administration of OPC31260 when the dis-
ease is already established either halts progression (PCK)
or causes regression (pcy) of disease. OPC31260 has also
been effective in the cpk mouse. The renal selectivity
(VPV2R expression restricted to collecting duct prin-
cipal cells and endothelial cells) and apparent safety of
these drugs in preclinical and clinical studies (for disor-
ders of water retention such as congestive heart failure
and cirrhosis) makes them particularly attractive. Clini-
cal trials for polycystic kidney disease are currently under
consideration.
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